BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

Eli Lilly and Nvidia are launching a joint artificial intelligence lab in South San Francisco with 70 people to speed up drug ...

Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal ...

By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

The company got some bad news to start 2026.

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

Retatrutide is an exciting GLP-1 drug that has explosive potential.

The companies will invest up to $1 billion over five years to support discovery and development powered by artificial ...

The gap may be too hard to close in the next 12 months.